| abstract |
The present invention relates to a chemical inhibitor of p53-Snail binding and to a pharmaceutical composition for treating cancer diseases containing the same as its active ingredient. The chemical inhibitor of p53-Snail binding induces expression of p-53 in K-Ras mutant cell lines, and thus can effectively treat or prevent K-Ras mutant cancer diseases that may not be easily diagnosed or treated, such as pancreatic cancer, lung cancer, cholangioma, and colon cancer. |